跳至主要内容
临床试验/NCT07653126
NCT07653126已完成不适用

Use of Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumour (NET) Patients in Germany - A Retrospective Evaluation in German Centers for NET (LUNET-2 Study)

Novartis Pharmaceuticals7 个研究点 分布在 1 个国家目标入组 117 人开始时间: 2023年4月3日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
117
试验地点
7

研究概览

简要总结

The aim of this study was to assess patient characteristics and treatment patterns of gastro-enteropancreatic neuroendocrine tumor (GEP-NET) patients who received PRRT in German routine care.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with a confirmed diagnosis of GEP-NET (any localization of the primary tumor including cancer of unknown primary origin [CUP], any Grade).
  • Patients with a first cycle of primary PRRT of home-brew 177Lu-DOTATATE/DOTATOC or Lutathera® between 01 July 2020 and 30 June 2021.

排除标准

  • Received a combination of PRRT with chemotherapy.
  • Received a combination of PRRT with a radionuclide other than lutetium-177 (e.g., yttrium-90).

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (7)

Loading locations...

相似试验